Phase 2 trial ‘STEM’ in metastatic breast cancer: With 18 out of the 60 patients in the trial having been dosed as of December 2017, an interim read-out is expected this quarter followed by final topline results in H2’2018E. A compassionate use programme, which allows patients to stay on the drug post trial end, has already been implemented.
25 Apr 2018
SFX-01 – Anticipating Two Positive Phase 2 Read-outs in 2018
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SFX-01 – Anticipating Two Positive Phase 2 Read-outs in 2018
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.42m
- Published:
25 Apr 2018 -
Author:
Barry Gibb -
Pages:
31
Phase 2 trial ‘STEM’ in metastatic breast cancer: With 18 out of the 60 patients in the trial having been dosed as of December 2017, an interim read-out is expected this quarter followed by final topline results in H2’2018E. A compassionate use programme, which allows patients to stay on the drug post trial end, has already been implemented.